Related Experiment Video
Updated: May 27, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
[Pharmacological treatment of acute hepatitis B]
Francisco Javier García-Alonso1, Rosa María Martín-Mateos, Víctor Moreira Vicente
1Hospital Universitario Ramón y Cajal, Madrid, España. fj.garcia.alonso@gmail.com
Abstract:
The incidence of acute B hepatitis is decreasing due to socioeconomical changes and the implementation of vaccination programs. Nevertheless it is potentially severe, causing approximately 30% of acute liver failures in Spain. Pharmacological treatment of acute B hepatitis has become a matter of issue over the last decade. This text offers a review of the published data and international guidelines. Most published studies have a low methodological quality and lamivudine was used as treatment in all of them. A survival improvement with prompt treatment has been shown in acute liver injury and probably in severe acute hepatitis (total bilirubin>10mg/dl and INR>1.5). International guidelines support treatment in these cases, but there is no consensus on the drug to use or the length of treatment.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Inhibitors of Viral Protein Synthesis
Pharmaceutical Poisoning: Treatment Strategies
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

